Biolife Solutions, Inc. · NASDAQ:BLFS

Biolife Solutions — Investor Presentation (March 2026)

28 slides from Biolife Solutions's investor presentation, Mar 2, 2026

1. Slide 1: Investor Presentation February 2026

   Investor Presentation February 2026

2. Slide 2: Safe Harbor Statement

   2 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 © Copyright 2026 BioLife Solutions® Safe Harbor Statement Certain statements contained in this presentation are not historical facts and may be forward- looking statements within the meaning of the Private Securities Litigation

3. Slide 3: Our Mission

   3 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 Our Mission Our mission is to protect the integrity of cells and provide trusted tools, services, and expertise that enable our customers to advance and de-risk the development and delivery of cell-based therapies © Copyright 20

4. Slide 4: BioLife at a Glance

   4 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 © Copyright 2026 BioLife Solutions® BioLife at a Glance Leading provider of biopreservation and processing tools for cell-based therapies Note: 2025 figures pro forma for the divestiture of evo. (1) Reflects specification of bot

5. Slide 5: Years of Innovation in Cell-Based Applications

   5 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 28 Years of Innovation in Cell-Based Applications 1987 - 2002 2003 - 2013 2014 - 2018 2023 - 20252019 - 2022 Scientific Foundation Biopreservation Focus Becoming Gold Standard Adjacency Expansion Cell Processing & Consumables Fo

6. Slide 6: Executed Successful Portfolio Refocusing

   6 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 Executed Successful Portfolio Refocusing Note: 2025 figures pro forma for the divestiture of evo. (1) Excludes prior-year COVID-related revenue. (2) Reflects cash & cash equivalents and short- and long-term assets held for sale

7. Slide 7: BioLife Supports Diverse Cell-Based Applications

   7 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 Genetic Modification Therapy Delivery Sample Collection Expansion (of gene- modified cells) BioLife Supports Diverse Cell-Based Applications BioLife provides solutions for therapies involving ex vivo cell processing Ex Vivo Cell

8. Slide 8: BioLife Solutions Product Platforms

   8 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 13% BioLife Solutions Product Platforms Cell Processing Tools BioLife’s cell processing tools support critical steps in the preparation, transfer, and recovery of cell-based therapies by enhancing efficiency and reproducibility

9. Slide 9: BioLife Differentiation and Key Products

   9 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 Pathogen-reduced and xeno-free supplements that support faster cell growth, higher yield, and improved functionality during cell expansion BioLife Differentiation Innovating vs. Traditional Options BioLife Solutions Key Products

10. Slide 10: BioLife Products Used Throughout a Typical Cell-Based Therapy Workflow

    10 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 BioLife Products Used Throughout a Typical Cell- Based Therapy Workflow Upstream Processing Downstream Processing Cells are collected from the patient or donor and sent to manufacturing Target cells are separated and purified f

11. Slide 11: Active US Commercially Sponsored Cell-Based Therapy Trials and Approved Therapies

    11 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 Active US, Commercially Sponsored Cell-Based Therapy Trials and US Approved Cell-Based Therapies A significant number of active clinical trials and commercial cell-based therapies are supported by BioLife’s biopreservation medi

12. Slide 12: Embedded Across Cell-Based Applications

    12 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 Embedded Across Cell-Based Applications Therapy Type Cell Source Therapeutic Area Breakdown of active US, commercially-sponsored cell-based therapy clinical trials in which biopreservation media is specified (N=~250) 59% 32% 9%

13. Slide 13: CryoStor: Industry-Leading Cryopreservation Solution with High Switching Costs

    13 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 CryoStor®: Industry-Leading Cryopreservation Solution in a Market with High Switching Costs CryoStor® Differentiation Obstacles to Switch by Phase Performance (Cell Viability) Regulatory Documentation Technical Support Supply C

14. Slide 14: Diversity of Products and Multi-Product Specification

    14 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 Diversity of Products and Multi-Product Specification Greater specification of non-CryoStor® products and increasing multi-product specification in global early-stage trials position BioLife for sustained growth Note: Reflects

15. Slide 15: Cell-Based Therapy Market Positioned To Grow 20%+

    15 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 +12% ‘25-’30 CAGR 23K 30K 50K33K Global Number of Cell-Based Therapy Patients (Clinical & Commercial) 34K 42K 59K 68K 74K 81K 89K $1.1 $1.7 $2.7 $3.8 $4.8 $6.7 $9.2 $12.1 $14.6 $17.0 $19.0 '20 '21 '22 '23 ' 4 '25F '26F '27F '28

16. Slide 16: Large ~$4B Total Addressable Market for BioLife

    16 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 Large ~$4B Total Addressable Market for BioLife Current Market Opportunity Breakdown (2025) Addressable by BioLife Today Future Expansion Potential Source: Advancy. Total Biopreservation and Cell Processing Tools Market Global

17. Slide 17: Customer Case Study: Trusted Partner Across the Workflow

    17 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 2021 2025 Customer Annual Revenue Customer Case Study: Trusted Partner for Solutions Across the Workflow Large biopharma with multiple commercial cell-based therapy programs Long-term relationship with customer across multiple

18. Slide 18: Organizational Overview

    18 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 Organizational Overview Organizational Breakdown by Functional Area 24% 21% 19% 13% 13% 10% ~155 Employees Quality Manufacturing Finance Sales & Marketing R&D Corporate & Other Executive Team Roderick de Greef Chairman & CEO Ab

19. Slide 19: Operational Footprint and Capabilities

    19 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 Operational Footprint and Capabilities Overview of Key Facilities Media Capacity Expansion (Bothell, WA) • Additional GMP cleanroom with fill & formulation capability • $5.5M total investment • Q1’2026 expected completion De No

20. Slide 20: BioLife Solutions Financial Overview

    20 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 © Copyright 2026 BioLife Solutions® BioLife Solutions Financial Overview Total Revenue ($M) Adjusted EBITDA ($M) $25 $16 $18 $19 $21 $22 $23 $26 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Key Future Growth Drivers +29% ‘24

21. Slide 21: Investment Highlights

    21 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 Investment Highlights (1) Based on EvaluatePharma. (2) Based on active US commercially sponsored cell-based therapy trials; reflects specification of biopreservation media products (CryoStor®, Hypothermosol® and/or other biopre

22. Slide 22: Pregening the preset ge

    Pregening the preset ge Solutions =) eo) > ~< = © os , Biolife \

23. Slide 23: GAAP to Non-GAAP Financial Information

    23 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 GAAP to Non-GAAP Financial Information © Copyright 2026 BioLife Solutions®

24. Slide 24: GAAP Gross Profit to Non-GAAP Gross Profit

    24 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 GAAP Gross Profit to Non-GAAP Gross Profit Estimated figures pro forma for the divestiture of evo (In thousands) Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY2024 Total revenues $ 16,485 $ 18,042 $ 19,405 $ 20,715 $ 74,647 Cost of revenue

25. Slide 25: GAAP Gross Profit to Non-GAAP Gross Profit

    25 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 GAAP Gross Profit to Non-GAAP Gross Profit Estimated figures pro forma for the divestiture of evo (In thousands) Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 Total revenues $ 22,054 $ 23,438 $ 25,958 $ 24,764 $ 96,214 Cost of revenu

26. Slide 26: GAAP to Non-GAAP Adjusted EBITDA

    26 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 GAAP to Non-GAAP Adjusted EBITDA Estimated figures pro forma for the divestiture of evo (In thousands) Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 Income (loss) from continuing operations $ (2,715) $ (5,158) $ 300 $ (1,216) $ (8,78

27. Slide 27: GAAP to Non-GAAP Adjusted EBITDA

    27 | Industry-Leading Solutions for Cell-Based Therapies | February 2026 GAAP to Non-GAAP Adjusted EBITDA Estimated figures pro forma for the divestiture of evo (In thousands) Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 Income (loss) from continuing operations $272 ($15,321) $811 $2,108 ($12,130) ADJUST

28. Slide 28: BioLife Solutions Inc. contact details

    © Copyright 2026 BioLife Solutions® BioLife Solutions Inc. 3303 Monte Villa Parkway, Suite 310 Bothell, WA 98021 USA T +1.866.424.6543 or 425.402.1400 F +1.425.402.1433 E info@biolifesolutions.com biolifesolutions.com NASDAQ: BLFS For additional questions or comments Roderick De Greef | Chief Execut

BioLife Solutions — Investor Presentation (March 2026) on 6ix